The surgical paradigm for metastatic colorectal cancer faces a critical reassessment following disappointing results from a major clinical trial. For decades, oncologists have expanded surgical removal of tumors from single-organ metastases to complex multi-organ resections, based on promising outcomes when cancer had spread only to the liver or lungs. The ORCHESTRA trial directly challenged this aggressive approach by testing whether extensive surgical debulking—removing as much tumor tissue as possible across multiple organs—actually improves survival compared to systemic therapy alone. The results were sobering: patients undergoing extensive surgery did not live longer than those receiving modern chemotherapy and targeted drugs without surgery. This finding contradicts the prevailing assumption that "more surgery equals better outcomes" for metastatic disease. The trial's negative results highlight a crucial limitation in cancer treatment logic. While removing isolated liver or lung metastases has proven beneficial, the biological reality of widespread metastatic disease appears fundamentally different. When colorectal cancer has seeded multiple organs, the remaining microscopic disease typically drives outcomes regardless of how much visible tumor surgeons remove. This represents a paradigm shift for surgical oncology, suggesting that patient selection criteria for metastasectomy need substantial refinement. The implications extend beyond colorectal cancer, potentially influencing surgical decisions across multiple tumor types where debulking procedures are considered. Rather than abandoning surgery entirely, the field must now focus on identifying the subset of patients most likely to benefit from resection while sparing others from potentially morbid procedures that offer no survival advantage.